Prostate cancer incidence and diagnosis in men with PSA levels >20 ng/ml: is it possible to decrease the number of biopsy cores?

References

• Na R, Ye D, Qi J, et al. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: results from a Multicenter Study in China. Prostate. 2017;77:1221–1229.
   PubMed Web of Science ®Google Scholar
• Torrealba N, Vera R, Fraile B, et al. TGF-beta/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer. Aging Male. 2019;1-11. DOI:10.1080/13685538.2019.1597840
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152:2037–2042.
   PubMed Web of Science ®Google Scholar
• Djavan B, Waldert M, Zlotta A, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol. 2001;166:856–860.
   PubMed Web of Science ®Google Scholar
• Philip J, Manikandan R, Javle P, et al. Prostate cancer diagnosis: should patients with prostate specific antigen >10ng/mL have stratified prostate biopsy protocols? Cancer Detect Prev. 2009;32:314–318.
   PubMedGoogle Scholar
• Loeb S, van den Heuvel S, Zhu X, et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012;61:1110–1114.
   PubMed Web of Science ®Google Scholar
• Ragavan N, Philip J, Balasubramanian SP, et al. A randomized, controlled trial comparing lidocaine periprostatic nerve block, diclofenac suppository and both for transrectal ultrasound guided biopsy of prostate. J Urol. 2005;174:510–513. discussion 513.
   PubMed Web of Science ®Google Scholar
• Hodge KK, McNeal JE, Stamey TA. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol. 1989;142:66–70.
   PubMed Web of Science ®Google Scholar
• Cormio L, Scattoni V, Lorusso F, et al. Prostate cancer detection rates in different biopsy schemes. Which cores for which patients? World J Urol. 2014;32:341–346.
   PubMed Web of Science ®Google Scholar
• EAU Guidelines. Edn. presented at the. ISBN 978-94-92671-01-1. EAU Annual Congress Copenhagen; 2018. Available from: www.uroweb.com
   Google Scholar
• Eichler K, Hempel S, Wilby J, et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175:1605–1612.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Roehrborn CG. Using biopsy to detect prostate cancer. Rev Urol. 2008;10:262–280.
   PubMedGoogle Scholar
• Kocan H. Factors affecting the diagnosis of prostate cancer through 12 quadrant guided prostate biopsy. Aging Male. 2019;1–6. DOI:10.1080/13685538.2019.1573219
   PubMed Web of Science ®Google Scholar
• Ghani KR, Dundas D, Patel U. Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and 12-core biopsy protocol. BJU Int. 2004;94:1014–1020.
   PubMed Web of Science ®Google Scholar
• Naughton CK, Miller DC, Mager DE, et al. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol. 2000;164:388–392.
   PubMed Web of Science ®Google Scholar
• Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. American Urological Association (AUA) Guideline; 2018. Available from: www.auanet.org
   Google Scholar
• Gerstenbluth RE, Seftel AD, Hampel N, et al. The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: is biopsy always required? J Urol. 2002;168:1990–1993.
   PubMed Web of Science ®Google Scholar
• Yang WJ, Lee DH, Chung BH, et al. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study. Urology. 2006;67:333–336.
   PubMed Web of Science ®Google Scholar
• Zhang LJ, Wu B, Zha ZL, et al. Perineural invasion as an independent predictor of biochemical recurrence in prostate cancer following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. BMC Urol. 2018;18:5.
   PubMed Web of Science ®Google Scholar
• Athanazio D, Gotto G, Shea-Budgell M, et al. Global Gleason grade groups in prostate cancer: concordance of biopsy and radical prostatectomy grades and predictors of upgrade and downgrade. Histopathology. 2017;70:1098–1106.
   PubMed Web of Science ®Google Scholar
• Lee IH, Roberts R, Shah RB, et al. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:1059–1064.
   PubMed Web of Science ®Google Scholar
• Vukovic M, Kavaric P, Magdelinic A, et al. Perineural invasion on biopsy specimen as predictor of tumor progression in aging male treated with radical prostatectomy. Could we use it for pre-surgical screening? Aging Male. 2019;1–6. DOI:10.1080/13685538.2019.1581758
   PubMed Web of Science ®Google Scholar
• Erdogan A, Polat S, Keskin E, et al. Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5-10 ng/mL and 10.1-30 ng/mL? Aging Male. 2019;1–7. DOI:10.1080/13685538.2019.1578741
   PubMed Web of Science ®Google Scholar
• Slater JM, Bush DA, Grove R, et al. The prognostic value of percentage of positive biopsy cores, percentage of cancer volume, and maximum involvement of biopsy cores in prostate cancer patients receiving proton and photon beam therapy. Technol Cancer Res Treat. 2014;13:227–231.
   PubMed Web of Science ®Google Scholar
• Vance SM, Stenmark MH, Blas K, et al. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:940–946.
   PubMed Web of Science ®Google Scholar